Datavault AI Inc. announced a significant step in the biotechnology sector by granting a $10 million worldwide exclusive license to Scilex Holding Company. This agreement, revealed on November 4, 2025, allows Scilex to utilize Datavault AI’s proprietary technology for the tokenization and monetization of real-world assets, particularly in genomic and drug data.
Based in Philadelphia, Datavault AI focuses on AI-driven blockchain solutions, emphasizing data monetization and asset tokenization. The newly licensed technology will enable Scilex to establish a Biotech Exchange platform. This platform aims to facilitate secure trading of biotech assets, including genomic data, diagnostic products, and therapeutic information.
Transforming Biotech Asset Management
This licensing agreement is a pivotal move toward commercializing innovations within the biotech and biopharma industries. Datavault AI estimates that tokenizing these assets could unlock approximately $2.0 trillion in pharmaceutical drug sales and diagnostic revenues. Furthermore, the tokenization approach offers companies a non-dilutive funding alternative for developing and marketing new products.
Datavault AI’s robust intellectual property portfolio underpins this agreement, featuring a key pending patent for a “Platform and Method for Tokenizing DNA Data” (U.S. Patent Application No. 17/941,623). This patent is crucial for creating a secure framework for the exchange of sensitive genetic information. The company holds a suite of additional issued and pending patents that support the Biotech Exchange, enhancing data security and monetization capabilities.
Among these patents is the “Platform for Management of User Data,” which focuses on secure data handling, and “Portfolio Driven Targeted Advertising Network,” designed for data-driven targeting in exchange ecosystems. Pending patents include various systems for tokenized asset minting, corporate data, and affiliate marketing, all aimed at fostering biotech partnerships.
Financial Implications and Future Prospects
Under the terms of the license agreement, Datavault AI will receive a non-refundable upfront fee of $10 million, paid in four installments of $2.5 million each, with deadlines set for December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Additionally, the company is eligible for sales milestone payments totaling up to $2.55 billion as Scilex meets predetermined sales targets.
This agreement builds upon Datavault AI’s previous collaborations, including a partnership with Brookhaven National Laboratory, where AI-driven supercomputing was applied in biofuel research. This history of leveraging advanced technologies for practical applications enhances the credibility of Datavault AI’s offerings.
As the biotech sector continues to evolve, the implications of this licensing agreement could be profound, potentially shaping the future of pharmaceutical asset management and monetization. Datavault AI positions itself at the forefront of this transformation, enabling secure and efficient trading of biotech data assets while ensuring compliance with privacy regulations.
For more information about Datavault AI, visit their official website at www.dvlt.ai.
Scilex Holding Company, headquartered in Palo Alto, California, focuses on developing and commercializing non-opioid pain management products. Their portfolio includes several FDA-approved therapies aimed at addressing acute and chronic pain, highlighting their commitment to improving patient outcomes.
As the landscape of biotech and pharmaceuticals shifts toward innovative technologies, this partnership represents a significant milestone in the commercialization of biotech assets and the advancement of secure, AI-driven solutions.
